Systemic therapy with biologics started for AD in September 2017 when the IL-4R blocking antibody dupilumab was approved21,22, and continued 2021 with the approval of the anti-IL-13 antibody tralokinumab, both targeting the type-2 inflammation axis. The gene discussed is IL13; the disease is Alzheimer disease.